Literature DB >> 24621674

Estimation and application of the minimum clinically important difference in COPD.

Paul W Jones1.   

Abstract

Mesh：

Year:  2014        PMID： 24621674     DOI： 10.1016/S2213-2600(14)70038-4

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN： 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  9 in total

1.  Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).

Authors:  Roland Buhl; François Maltais; Roger Abrahams; Leif Bjermer; Eric Derom; Gary Ferguson; Matjaž Fležar; Jacques Hébert; Lorcan McGarvey; Emilio Pizzichini; Jim Reid; Antony Veale; Lars Grönke; Alan Hamilton; Lawrence Korducki; Kay Tetzlaff; Stella Waitere-Wijker; Henrik Watz; Eric Bateman
Journal:  Eur Respir J       Date:  2015-01-08       Impact factor: 16.671

2.  Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age.

Authors:  Gary T Ferguson; Jill P Karpel; Emmanuelle Clerisme-Beaty; Lars Grönke; Florian Voß; Roland Buhl
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-10-31

3.  The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.

Authors:  Masakazu Ichinose; Hiroyuki Taniguchi; Ayako Takizawa; Lars Grönke; Lazaro Loaiza; Florian Voß; Yihua Zhao; Yoshinosuke Fukuchi
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-08-29

4.  Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.

Authors:  Gary T Ferguson; Jill Karpel; Nathan Bennett; Emmanuelle Clerisme-Beaty; Lars Grönke; Florian Voß; Roland Buhl
Journal:  NPJ Prim Care Respir Med       Date:  2017-02-02       Impact factor: 2.871

Review 5.  Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review.

Authors:  Jose Luis Lopez-Campos; Carmen Calero-Acuña; Eduardo Márquez-Martín; Esther Quintana Gallego; Laura Carrasco-Hernández; Maria Abad Arranz; Francisco Ortega Ruiz
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-06-23

6.  Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial.

Authors:  Klaus F Rabe; David M G Halpin; MeiLan K Han; Marc Miravitlles; Dave Singh; Lars Grönke; Florian Voß; Fernando J Martinez
Journal:  Respir Res       Date:  2020-07-09

7.  Tiotropium treatment for bronchiectasis: a randomised, placebo-controlled, crossover trial.

Authors:  Lata Jayaram; Alain C Vandal; Catherina L Chang; Chris Lewis; Cecilia Tong; Christine Tuffery; Jill Bell; Wendy Fergusson; Gene Jeon; David Milne; Stuart Jones; Noel Karalus; Sandra Hotu; Conroy Wong
Journal:  Eur Respir J       Date:  2022-06-09       Impact factor: 33.795

8.  Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk.

Authors:  Henry Covelli; Bonavuth Pek; Isabelle Schenkenberger; Catherine Scott-Wilson; Amanda Emmett; Courtney Crim
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-12-18

9.  Minimal important difference and responsiveness of 2-minute walk test performance in people with COPD undergoing pulmonary rehabilitation.

Authors:  Kylie Nicole Johnston; Adrian James Potter; Anna Caroline Phillips
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-10-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.